IAP抑制增强直肠癌临床前模型放化疗应答
该研究基于42例局部晚期直肠癌新辅助放疗前后活检转录组分析,发现放疗上调TNFα/TNFR1凋亡信号但抗凋亡信号也升高;临床相关IAP拮抗剂tolinapant可降解cIAP1/2、增强放疗和化疗诱导的凋亡,并抑制5FU诱导的耐药持留细胞,为联合IAP拮抗剂提高全程新辅助治疗疗效提供机制依据。
要点
- 放疗上调直肠癌TNFα/TNFR1及凋亡基因集,同时抗凋亡信号升高可能限制应答。
- Tolinapant降解cIAP1/2,增强放疗诱导的直肠癌模型凋亡。
- Tolinapant增强化疗凋亡并抑制5FU诱导的耐药持留细胞。
核心结论
- TNFα相关凋亡信号是直肠癌放疗诱导的潜在脆弱点,联合IAP拮抗剂可增强放化疗应答并抑制耐药持留细胞。
研究设计与样本
- 对42例直肠癌患者新辅助放疗两周前后的肿瘤活检进行转录组分析。
- 在直肠癌模型中评估tolinapant对cIAP1/2降解、放化疗诱导凋亡及5FU诱导DTP细胞形成的影响,并在SW837异种移植模型评估体内疗效。
主要发现
- 放疗诱导TNFα/TNFR1信号和凋亡相关基因集显著上调,GSEA确认「TNFα signalling via NFκB」和「Apoptosis」通路富集。
- TNF、TNFRSF1A、RIPK1、TRADD和CFLAR(FLIP)上调,DIABLO下调。
- Tolinapant降解cIAP1/2并显著增强放疗诱导的直肠癌模型凋亡,TNFα共处理经caspase-8依赖机制进一步放大凋亡。
- Tolinapant联合放疗在体内耐受良好,SW837异种移植瘤体积较单放疗缩小但差异未达统计学显著。
- Tolinapant增强化疗诱导凋亡并防止5FU诱导的DTP直肠癌细胞出现。
临床怎么用
- 机制上支持在直肠癌全程新辅助治疗中联合IAP拮抗剂以增强放化疗应答并减少耐药持留。
局限性
- 体内联合放疗较单放疗的肿瘤体积差异未达统计学显著。
- 研究为临床前模型,尚需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The modern management of locally advanced rectal cancer (LARC) involves sequential radiotherapy and chemotherapy, termed Total Neoadjuvant Therapy (TNT). Although TNT significantly improves tumour regression and achieves complete response rates of approximately 30 %, treatment efficacy remains limited in part by tumour-intrinsic resistance to apoptosis. We therefore sought to investigate the effects of radiotherapy on TNFα-associated apoptotic signalling in rectal cancer and evaluate whether inhibition of Inhibitor of Apoptosis Proteins (IAPs) could enhance treatment response. METHODS: Transcriptomic profiling was performed on rectal tumour biopsies obtained before and after two weeks of neoadjuvant radiotherapy (n = 42). Gene Set Enrichment Analysis was used to identify pathways altered following radiotherapy. The clinically relevant IAP antagonist, tolinapant, was evaluated in rectal cancer models to assess effects on cIAP1/2 degradation, radiation- and chemotherapy-induced apoptosis, and formation of 5-fluorouracil (5FU)-induced drug-tolerant persister (DTP) cells. Mechanistic studies were performed in the presence of TNFα, and in vivo efficacy was assessed in SW837 xenograft models. RESULTS: Radiotherapy induced robust upregulation of TNFα/TNFR1 signalling and apoptosis-associated gene sets. Gene Set Enrichment Analysis confirmed enrichment of both "TNFα signalling via NFκB" and "Apoptosis" pathways. Upregulation of TNF, TNFRSF1A, RIPK1, TRADD, and CFLAR (FLIP) was observed alongside downregulation of DIABLO, suggesting that radiotherapy primes tumours for TNFα-mediated apoptosis but that elevated antiapoptotic signalling may suppress this response. Tolinapant degraded cIAP1/2 and significantly enhanced radiation-induced apoptosis in rectal cancer models. Co-treatment with TNFα further amplified apoptosis through a caspase-8-dependent mechanism. The combination of tolinapant and radiation was well-tolerated in vivo and reduced SW837 xenograft tumour volume compared to radiation alone; however, this difference did not meet statistical significance. Tolinapant also potentiated chemotherapy-induced apoptosis and prevented the emergence of 5FU-induced DTP rectal cancer cells. CONCLUSION: These findings identify TNFα-associated apoptotic signalling as a potential radiation-induced vulnerability in rectal cancer and provide a mechanistic rationale for combining radiotherapy with IAP antagonists. Tolinapant also enhanced apoptosis induced by chemotherapy whilst suppressing drug-tolerant persisters, supporting further investigation of IAP antagonism as a strategy to improve TNT efficacy in the neoadjuvant management of rectal cancer.
引用
- O'Brien T, Wright T, Downs M, et al. IAP inhibition enhances response to radiotherapy and chemotherapy in preclinical models of rectal cancer. Radiother Oncol. 2026. PMID: 42925957. doi:10.1016/j.radonc.2026.111832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。